Investigating a new target for treating ovarian cancer
Targeting RHNO1 in Ovarian Cancer
This study is looking at a protein called RHNO1 to see how it affects treatment for high-grade serous ovarian cancer, with the goal of finding new drugs that can help patients respond better to chemotherapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10813210 on NIH RePORTER |
What this research studies
This research focuses on high-grade serous ovarian cancer, the most common and deadly form of ovarian cancer. It aims to understand the role of a protein called RHNO1, which is involved in the cancer's response to DNA replication stress and chemotherapy resistance. By using advanced techniques like CRISPR to manipulate RHNO1 in cancer cells, the researchers hope to develop new drugs that can effectively target this protein and improve treatment outcomes for patients. The study will also explore the effects of these potential therapies in live models of ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade serous ovarian cancer, particularly those with recurrent or chemoresistant disease.
Not a fit: Patients with other subtypes of ovarian cancer or those who are not experiencing recurrence may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for patients with high-grade serous ovarian cancer.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, indicating that this approach could be effective.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Karpf, Adam R. — University of Nebraska Medical Center
- Study coordinator: Karpf, Adam R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.